A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.

Trial Profile

A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs ARGX 110 (Primary)
  • Indications Cancer; Cutaneous T cell lymphoma; Haematological malignancies; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors argenx
  • Most Recent Events

    • 25 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 11 Dec 2017 According to an argenx media release, interim results will be presented during a workshop being held in conjunction with the American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2017 .
    • 11 Dec 2017 Interim results (n=22) presented in an argenx Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top